Bierer S - Search Results

1

Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.

Herrmann E, Gerss J, Bierer S, Köpke T, Bolenz C, Hertle L, Wülfing C. Herrmann E, et al. Among authors: bierer s. J Cancer Res Clin Oncol. 2009 Jan;135(1):61-7. doi: 10.1007/s00432-008-0438-7. Epub 2008 Jul 1. J Cancer Res Clin Oncol. 2009. PMID: 18592270

2

Update on systemic therapies of metastatic renal cell carcinoma.

Herrmann E, Bierer S, Wülfing C. Herrmann E, et al. Among authors: bierer s. World J Urol. 2010 Jun;28(3):303-9. doi: 10.1007/s00345-010-0519-5. Epub 2010 Feb 24. World J Urol. 2010. PMID: 20180125 Review.

3

Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.

Riesenbeck LM, Bierer S, Hoffmeister I, Köpke T, Papavassilis P, Hertle L, Thielen B, Herrmann E. Riesenbeck LM, et al. Among authors: bierer s. World J Urol. 2011 Dec;29(6):807-13. doi: 10.1007/s00345-010-0627-2. Epub 2010 Dec 14. World J Urol. 2011. PMID: 21153827

4

Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.

Herrmann E, Brinkmann OA, Bode ME, Bierer S, Köpke T, Bögemann M, Hertle L, Wülfing C. Herrmann E, et al. Among authors: bierer s. Eur Urol. 2007 Jun;51(6):1625-31; discussion 1631-2. doi: 10.1016/j.eururo.2006.11.003. Epub 2006 Nov 13. Eur Urol. 2007. PMID: 17113215

5

The role of the endothelin axis and microvessel density in bladder cancer - correlation with tumor angiogenesis and clinical prognosis.

Herrmann E, Bögemann M, Bierer S, Eltze E, Toma MI, Köpke T, Hertle L, Wülfing C. Herrmann E, et al. Among authors: bierer s. Oncol Rep. 2007 Jul;18(1):133-8. Oncol Rep. 2007. PMID: 17549358

6

Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.

Herrmann E, Bierer S, Gerss J, Köpke T, Hertle L, Wülfing C. Herrmann E, et al. Among authors: bierer s. Oncology. 2008;74(3-4):216-22. doi: 10.1159/000151369. Epub 2008 Aug 20. Oncology. 2008. PMID: 18714170

7

[New markers for pharmacological targeting in bladder cancer with lymph node metastasis].

Herrmann E, Eltze E, Köpke T, Bolenz C, Bierer S, Neumann J, Hertle L, Wülfing C. Herrmann E, et al. Among authors: bierer s. Aktuelle Urol. 2007 Sep;38(5):392-7. doi: 10.1055/s-2007-980110. Aktuelle Urol. 2007. PMID: 17907066 German.

8

[New therapeutic regimes in metastasic renal-cell carcinoma].

Bierer S, Hertle L, Nitschmann S. Bierer S, et al. Internist (Berl). 2008 Jan;49(1):114-7. doi: 10.1007/s00108-007-1972-0. Internist (Berl). 2008. PMID: 18704353 German. No abstract available.

9

Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma.

Bierer S, Herrmann E, Köpke T, Neumann J, Eltze E, Hertle L, Wülfing C. Bierer S, et al. Oncol Rep. 2008 Oct;20(4):721-5. Oncol Rep. 2008. PMID: 18813809

10

Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival.

Wülfing C, Eltze E, Yamini J, Wülfing P, Bierer S, Böcker W, Hertle L, Semjonow A, Sievert KD. Wülfing C, et al. Among authors: bierer s. Eur Urol. 2005 May;47(5):593-600. doi: 10.1016/j.eururo.2004.12.019. Epub 2005 Jan 26. Eur Urol. 2005. PMID: 15826749

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters